Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

ReoPro safe and effective in high-risk PTCA patients

July 1, 1997

Modified t-PA from Eisai highly effective thrombolytic

July 1, 1997

TIMI-IIA finds enoxaparin promising

July 1, 1997

New indication for enoxaparin recommended for approval

June 27, 1997

Thrombin inhibitors from Akzo Nobel

June 27, 1997

Orally active antithrombotic agents described by Pfizer

June 27, 1997

S.c. lepirudin vs. i.v. heparin for deep vein thrombosis

June 23, 1997

NicOx reveals antiinflammatory/antithrombotic compounds with low toxicity

June 20, 1997

RPR seeks approval for enoxaparin for unstable angina in Europe

June 18, 1997

3-Dimensional Pharmaceuticals licenses thrombin inhibitors to Wyeth-Ayerst

June 17, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...